Back to Search Start Over

Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up.

Authors :
Kerr KM
Elliott CG
Chin K
Benza RL
Channick RN
Davis RD
He F
LaCroix A
Madani MM
McLaughlin VV
Park M
Robbins IM
Tapson VF
Terry JR
Test VJ
Jain S
Auger WR
Source :
Chest [Chest] 2021 Nov; Vol. 160 (5), pp. 1822-1831. Date of Electronic Publication: 2021 Jun 04.
Publication Year :
2021

Abstract

Background: The United States Chronic Thromboembolic Pulmonary Hypertension Registry (US-CTEPH-R) was designed to characterize the demographic characteristics, evaluation, clinical course, and outcomes of surgical and nonsurgical therapies for patients with chronic thromboembolic pulmonary hypertension.<br />Research Question: What are the differences in baseline characteristics and 1-year outcomes between operated and nonoperated subjects?<br />Study Design and Methods: This study describes a multicenter, prospective, longitudinal, observational registry of patients newly diagnosed (< 6 months) with CTEPH. Inclusion criteria required a mean pulmonary artery pressure ≥ 25 mm Hg documented by right heart catheterization and radiologic confirmation of CTEPH. Between 2015 and 2018, a total of 750 patients were enrolled and followed up biannually until 2019.<br />Results: Most patients with CTEPH (87.9%) reported a history of acute pulmonary embolism. CTEPH diagnosis delays were frequent (median, 10 months), and most patients reported World Health Organization functional class 3 status at enrollment with a median mean pulmonary artery pressure of 44 mm Hg. The registry cohort was subdivided into Operable patients undergoing pulmonary thromboendarterectomy (PTE) surgery (n = 566), Operable patients who did not undergo surgery (n = 88), and those who were Inoperable (n = 96). Inoperable patients were older than Operated patients; less likely to be obese; have a DVT history, non-type O blood group, or thrombophilia; and more likely to have COPD or a history of cancer. PTE resulted in a median pulmonary vascular resistance decline from 6.9 to 2.6 Wood units (P < .001) with a 3.9% in-hospital mortality. At 1-year follow-up, Operated patients were less likely treated with oxygen, diuretics, or pulmonary hypertension-targeted therapy compared with Inoperable patients. A larger percentage of Operated patients were World Health Organization functional class 1 or 2 at 1 year (82.9%) compared with the Inoperable (48.2%) and Operable/No Surgery (56%) groups (P < .001).<br />Interpretation: Differences exist in the clinical characteristics between patients who exhibited operable CTEPH and those who were inoperable, with the most favorable 1-year outcomes in those who underwent PTE surgery.<br />Clinical Trial Registration: ClinicalTrials.gov; No.: NCT02429284; URL: www.clinicaltrials.gov.<br /> (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1931-3543
Volume :
160
Issue :
5
Database :
MEDLINE
Journal :
Chest
Publication Type :
Academic Journal
Accession number :
34090871
Full Text :
https://doi.org/10.1016/j.chest.2021.05.052